PathKeeper Surgical Celebrates the First Spine Surgery Performed with the PathKeeper 3D Optical Navigation System in Massachusetts

PathKeeper Surgical, a privately-held, Israel-based, medical technology company, dedicated to improving the health of individuals around the world suffering from all spinal issues requiring surgery. While celebrating the first use of the PathKeeper 3D optical navigation system during a spinal fusion surgery at Southcoast Health’s St. Luke’s Hospital in New Bedford, Massachusetts, PathKeeper Surgical strives to make navigation-guided surgery available to any patient in all operating rooms.

The PathKeeper system was utilized to create a comprehensive surgical plan and accurately navigate the single-level, lumbar degenerative spinal fusion surgery at Southcoast Health’s St. Luke’s Hospital.

“The PathKeeper system addresses many of the intricacies of spine surgery and adjusts to individual patient needs with a high level of accuracy and no radiation during a crucial part of the surgical procedure,” said Matthew Philips, MD, Chief of Brain & Spine Services, Southcoast Health Neurosurgery, Dartmouth, MA. “We have already experienced the clinical benefits of incorporating the PathKeeper system into our spinal fusion surgeries at St. Luke’s Hospital.”

The PathKeeper system was designed to replace traditional navigation technology with a 3D optical navigation system that offers comprehensive surgical planning; active, independent, submillimeter registration and tracking of the patient anatomy and surgical instruments; pinpoint accuracy of device implantation; more efficient surgical workflow; elimination of radiation exposure during the surgical procedure; and a more economical price so both the hospital and ambulatory-surgical center operating rooms can incorporate this new technology.

“We are thrilled at the adoption of the PathKeeper system at Southcoast Health, which continues our expansion of the PathKeeper system to hospitals and surgery centers across the United States,” said Ryan LeBlanc, Chief Commercial Officer, PathKeeper Surgical. “The PathKeeper system is a game changer in driving improved clinical outcomes and economic value to patients and healthcare providers.”

PathKeeper Surgical received its FDA 510k clearance earlier this year for the PathKeeper system. The name PathKeeper effectively describes the essence of the system – a 3D optical navigation system that ‘keeps’ the surgical ‘path’ on course throughout the surgery.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.
The combined expertise of Cordance Medical and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
Medixine prepares for 2024 with two key senior hires, VP of Operations in the U.S. and VP of Engineering in Finland. The appointments will enhance support and service to the company’s U.S.-based partners, including leading respiratory homecare provider Lincare and a major medical device manufacturer. In addition, the new hires will enable streamlined design, testing, and deployment of new product features for more patient-centric, cost and time-effective treatment of chronic conditions.
Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.
Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

By using this website you agree to accept Medical Device News Magazine Privacy Policy